EP3297608 - COMBINATION HIV THERAPEUTIC [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 19.05.2023 Database last updated on 03.09.2024 | |
Former | The patent has been granted Status updated on 10.06.2022 | ||
Former | Grant of patent is intended Status updated on 24.02.2022 | ||
Former | Examination is in progress Status updated on 24.04.2020 | ||
Former | Request for examination was made Status updated on 23.02.2018 | ||
Former | The international publication has been made Status updated on 02.12.2016 | Most recent event Tooltip | 09.02.2024 | Lapse of the patent in a contracting state New state(s): IT | published on 13.03.2024 [2024/11] | Applicant(s) | For all designated states APHIOS CORPORATION 3-E Gill Street Woburn, MA 01801 / US | [2018/13] | Inventor(s) | 01 /
CASTOR, Trevor Percival 469 Mystic Street Arlington, MA 02474 / US | [2018/13] | Representative(s) | Vossius, Corinna, et al Corinna Vossius IP Group Patent- und Rechtsanwaltskanzlei Buchenstraße 17 82064 Straßlach-Dingharting / DE | [2022/28] |
Former [2018/13] | Vossius, Corinna Corinna Vossius IP Group Patent- und Rechtsanwaltskanzlei Widenmayerstrasse 43 80538 München / DE | Application number, filing date | 16800598.1 | 23.05.2016 | [2018/13] | WO2016US33766 | Priority number, date | US201562165444P | 22.05.2015 Original published format: US 201562165444 P | [2018/13] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016191363 | Date: | 01.12.2016 | Language: | EN | [2016/48] | Type: | A1 Application with search report | No.: | EP3297608 | Date: | 28.03.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.12.2016 takes the place of the publication of the European patent application. | [2018/13] | Type: | B1 Patent specification | No.: | EP3297608 | Date: | 13.07.2022 | Language: | EN | [2022/28] | Search report(s) | International search report - published on: | US | 01.12.2016 | (Supplementary) European search report - dispatched on: | EP | 13.12.2018 | Classification | IPC: | A61K9/14, A61K31/366, A61P31/18, A61K38/15, A61K31/167, A61K31/19, A61K31/325, A61K31/4045, A61K47/69, A61P31/12, A61K9/127, A61K31/20, A61K31/365, A61K47/68 | [2019/03] | CPC: |
A61K9/1271 (EP,US);
A61K31/167 (EP,US);
A61K31/19 (EP,US);
A61K31/20 (EP,US);
A61K31/325 (EP,US);
A61K31/365 (EP,US);
A61K31/4045 (EP,US);
A61K38/15 (EP,US);
A61K47/6851 (EP,US);
A61K47/6913 (EP,US);
A61P31/12 (EP,US);
Y10S977/773 (EP,US);
| C-Set: |
A61K31/167, A61K2300/00 (US,EP);
A61K31/20, A61K2300/00 (US,EP);
A61K31/365, A61K2300/00 (EP,US);
A61K31/4045, A61K2300/00 (US,EP) |
Former IPC [2018/13] | A61K9/14, A61K31/366, A61P31/18 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/13] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | KOMBINIERTES HIV-THERAPEUTIKUM | [2018/13] | English: | COMBINATION HIV THERAPEUTIC | [2018/13] | French: | THÉRAPEUTIQUE COMBINÉE CONTRE LE VIH | [2018/13] | Entry into regional phase | 19.12.2017 | National basic fee paid | 19.12.2017 | Search fee paid | 19.12.2017 | Designation fee(s) paid | 19.12.2017 | Examination fee paid | Examination procedure | 19.12.2017 | Examination requested [2018/13] | 19.12.2017 | Date on which the examining division has become responsible | 25.09.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 20.11.2019 | Amendment by applicant (claims and/or description) | 29.04.2020 | Despatch of a communication from the examining division (Time limit: M04) | 20.08.2020 | Reply to a communication from the examining division | 19.02.2021 | Despatch of a communication from the examining division (Time limit: M04) | 05.05.2021 | Reply to a communication from the examining division | 25.02.2022 | Communication of intention to grant the patent | 02.06.2022 | Fee for grant paid | 02.06.2022 | Fee for publishing/printing paid | 02.06.2022 | Receipt of the translation of the claim(s) | Opposition(s) | 14.04.2023 | No opposition filed within time limit [2023/25] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 28.11.2019 | Request for further processing filed | 28.11.2019 | Full payment received (date of receipt of payment) Request granted | 03.01.2020 | Decision despatched | The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application | 20.11.2019 | Request for further processing filed | 20.11.2019 | Full payment received (date of receipt of payment) Request granted | 03.01.2020 | Decision despatched | Fees paid | Renewal fee | 29.05.2018 | Renewal fee patent year 03 | 28.05.2019 | Renewal fee patent year 04 | 18.05.2020 | Renewal fee patent year 05 | 25.05.2021 | Renewal fee patent year 06 | 09.05.2022 | Renewal fee patent year 07 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 13.07.2022 | AT | 13.07.2022 | CZ | 13.07.2022 | DK | 13.07.2022 | EE | 13.07.2022 | ES | 13.07.2022 | FI | 13.07.2022 | HR | 13.07.2022 | IT | 13.07.2022 | LT | 13.07.2022 | LV | 13.07.2022 | MC | 13.07.2022 | NL | 13.07.2022 | PL | 13.07.2022 | RO | 13.07.2022 | RS | 13.07.2022 | SE | 13.07.2022 | SI | 13.07.2022 | SK | 13.07.2022 | SM | 13.07.2022 | NO | 13.10.2022 | GR | 14.10.2022 | IS | 13.11.2022 | PT | 14.11.2022 | [2024/11] |
Former [2024/09] | AL | 13.07.2022 | |
AT | 13.07.2022 | ||
CZ | 13.07.2022 | ||
DK | 13.07.2022 | ||
EE | 13.07.2022 | ||
ES | 13.07.2022 | ||
FI | 13.07.2022 | ||
HR | 13.07.2022 | ||
LT | 13.07.2022 | ||
LV | 13.07.2022 | ||
MC | 13.07.2022 | ||
NL | 13.07.2022 | ||
PL | 13.07.2022 | ||
RO | 13.07.2022 | ||
RS | 13.07.2022 | ||
SE | 13.07.2022 | ||
SI | 13.07.2022 | ||
SK | 13.07.2022 | ||
SM | 13.07.2022 | ||
NO | 13.10.2022 | ||
GR | 14.10.2022 | ||
IS | 13.11.2022 | ||
PT | 14.11.2022 | ||
Former [2023/37] | AL | 13.07.2022 | |
AT | 13.07.2022 | ||
CZ | 13.07.2022 | ||
DK | 13.07.2022 | ||
EE | 13.07.2022 | ||
ES | 13.07.2022 | ||
FI | 13.07.2022 | ||
HR | 13.07.2022 | ||
LT | 13.07.2022 | ||
LV | 13.07.2022 | ||
NL | 13.07.2022 | ||
PL | 13.07.2022 | ||
RO | 13.07.2022 | ||
RS | 13.07.2022 | ||
SE | 13.07.2022 | ||
SI | 13.07.2022 | ||
SK | 13.07.2022 | ||
SM | 13.07.2022 | ||
NO | 13.10.2022 | ||
GR | 14.10.2022 | ||
IS | 13.11.2022 | ||
PT | 14.11.2022 | ||
Former [2023/29] | AL | 13.07.2022 | |
AT | 13.07.2022 | ||
CZ | 13.07.2022 | ||
DK | 13.07.2022 | ||
EE | 13.07.2022 | ||
ES | 13.07.2022 | ||
FI | 13.07.2022 | ||
HR | 13.07.2022 | ||
LT | 13.07.2022 | ||
LV | 13.07.2022 | ||
NL | 13.07.2022 | ||
PL | 13.07.2022 | ||
RO | 13.07.2022 | ||
RS | 13.07.2022 | ||
SE | 13.07.2022 | ||
SK | 13.07.2022 | ||
SM | 13.07.2022 | ||
NO | 13.10.2022 | ||
GR | 14.10.2022 | ||
IS | 13.11.2022 | ||
PT | 14.11.2022 | ||
Former [2023/23] | AT | 13.07.2022 | |
CZ | 13.07.2022 | ||
DK | 13.07.2022 | ||
EE | 13.07.2022 | ||
ES | 13.07.2022 | ||
FI | 13.07.2022 | ||
HR | 13.07.2022 | ||
LT | 13.07.2022 | ||
LV | 13.07.2022 | ||
NL | 13.07.2022 | ||
PL | 13.07.2022 | ||
RO | 13.07.2022 | ||
RS | 13.07.2022 | ||
SE | 13.07.2022 | ||
SK | 13.07.2022 | ||
SM | 13.07.2022 | ||
NO | 13.10.2022 | ||
GR | 14.10.2022 | ||
IS | 13.11.2022 | ||
PT | 14.11.2022 | ||
Former [2023/22] | AT | 13.07.2022 | |
CZ | 13.07.2022 | ||
DK | 13.07.2022 | ||
ES | 13.07.2022 | ||
FI | 13.07.2022 | ||
HR | 13.07.2022 | ||
LT | 13.07.2022 | ||
LV | 13.07.2022 | ||
NL | 13.07.2022 | ||
PL | 13.07.2022 | ||
RO | 13.07.2022 | ||
RS | 13.07.2022 | ||
SE | 13.07.2022 | ||
SM | 13.07.2022 | ||
NO | 13.10.2022 | ||
GR | 14.10.2022 | ||
IS | 13.11.2022 | ||
PT | 14.11.2022 | ||
Former [2023/21] | DK | 13.07.2022 | |
ES | 13.07.2022 | ||
FI | 13.07.2022 | ||
HR | 13.07.2022 | ||
LT | 13.07.2022 | ||
LV | 13.07.2022 | ||
NL | 13.07.2022 | ||
PL | 13.07.2022 | ||
RS | 13.07.2022 | ||
SE | 13.07.2022 | ||
SM | 13.07.2022 | ||
NO | 13.10.2022 | ||
GR | 14.10.2022 | ||
IS | 13.11.2022 | ||
PT | 14.11.2022 | ||
Former [2023/20] | ES | 13.07.2022 | |
FI | 13.07.2022 | ||
HR | 13.07.2022 | ||
LT | 13.07.2022 | ||
LV | 13.07.2022 | ||
NL | 13.07.2022 | ||
PL | 13.07.2022 | ||
RS | 13.07.2022 | ||
SE | 13.07.2022 | ||
SM | 13.07.2022 | ||
NO | 13.10.2022 | ||
GR | 14.10.2022 | ||
IS | 13.11.2022 | ||
PT | 14.11.2022 | ||
Former [2023/12] | ES | 13.07.2022 | |
FI | 13.07.2022 | ||
HR | 13.07.2022 | ||
LT | 13.07.2022 | ||
LV | 13.07.2022 | ||
NL | 13.07.2022 | ||
PL | 13.07.2022 | ||
RS | 13.07.2022 | ||
SE | 13.07.2022 | ||
NO | 13.10.2022 | ||
GR | 14.10.2022 | ||
IS | 13.11.2022 | ||
PT | 14.11.2022 | ||
Former [2023/11] | ES | 13.07.2022 | |
FI | 13.07.2022 | ||
HR | 13.07.2022 | ||
LT | 13.07.2022 | ||
LV | 13.07.2022 | ||
NL | 13.07.2022 | ||
PL | 13.07.2022 | ||
RS | 13.07.2022 | ||
SE | 13.07.2022 | ||
NO | 13.10.2022 | ||
GR | 14.10.2022 | ||
PT | 14.11.2022 | ||
Former [2023/10] | ES | 13.07.2022 | |
FI | 13.07.2022 | ||
HR | 13.07.2022 | ||
LT | 13.07.2022 | ||
LV | 13.07.2022 | ||
NL | 13.07.2022 | ||
RS | 13.07.2022 | ||
SE | 13.07.2022 | ||
NO | 13.10.2022 | ||
GR | 14.10.2022 | ||
PT | 14.11.2022 | ||
Former [2023/09] | ES | 13.07.2022 | |
FI | 13.07.2022 | ||
LT | 13.07.2022 | ||
LV | 13.07.2022 | ||
NL | 13.07.2022 | ||
RS | 13.07.2022 | ||
SE | 13.07.2022 | ||
NO | 13.10.2022 | ||
PT | 14.11.2022 | ||
Former [2023/08] | ES | 13.07.2022 | |
FI | 13.07.2022 | ||
LT | 13.07.2022 | ||
NL | 13.07.2022 | ||
RS | 13.07.2022 | ||
SE | 13.07.2022 | ||
NO | 13.10.2022 | ||
Former [2023/06] | NL | 13.07.2022 | Documents cited: | Search | [XYI]US2010166806 (CASTOR TREVOR PERCIVAL [US]) [X] 1-3,6,11 * claims 1-13 * * abstract * * paragraphs [0036] , [0037] * * figures 10,11; examples 9,10 * [Y] 1-15 [I] 4,5,7-10,12-15; | [Y]US2010247620 (CASTOR TREVOR PERCIVAL [US]) [Y] 1-15 * claims 1-9 *; | [Y]US2013156822 (CASTOR TREVOR PERCIVAL [US]) [Y] 1-15* claims 1-13 *; | [XYI]WO2013165592 (VOLPE JOSEPH M [US]) [X] 1-3,11 * claims 1-30 * [Y] 1-15 [I] 4,5; | [IY] - MOISES PEREZ ET AL, "Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency", CURRENT HIV RESEARCH, NL, (20100901), vol. 8, no. 6, doi:10.2174/157016210793499312, ISSN 1570-162X, pages 418 - 429, XP055530197 [I] 1-15 * abstract * * table 1 * * figure 5 * * "Results", "Discussion" * [Y] 1-15 DOI: http://dx.doi.org/10.2174/157016210793499312 | International search | [XY]US2010166806 (CASTOR TREVOR PERCIVAL [US]) [X] 1-3, 5-6, 11-13, 15-16, 24 * ; abstract; figure 10; paragraph [0028], [0037], [0046], [0050]; claim 13 * [Y] 4, 7, 9-10, 14, 17, 19-22, 25; | [Y]WO2015066535 (UNIV YALE [US]) [Y] 7, 10, 17, 20, 22 * ; page 2, lines 10-20; page 42, lines 1-5; page 43, lines 15-20; page 69, lines 20-25 *; | [Y] - SCHLICHTER, LM et al., "Successful Treatment of Murine Melanoma with Bryostatin 1.", CANCER RESEARCH, (19910115), vol. 51, pages 682 - 687, XP055334037 [Y] 4, 14 * ; abstract; page 682, column 2, paragraph 4 * | [Y] - WINDBERGS, M et al., "Biodegradable Core-Shell Carriers for Simultaneous Encapsulation of Synergistic Actives.", Journal of the American Chemical Society, (20130430), vol. 135, pages 7933 - 7937, XP055334043 [Y] 9-10, 19-22, 25 * ; abstract; page 7934, column 1, paragraph 1; page 7934, figure 2a-b * DOI: http://dx.doi.org/10.1021/ja401422r | [A] - BANDYOPADHYAY, A et al., "The impact of nanoparticle ligand density on dendritic- cell targeted vaccines.", Biomaterials, (20110400), vol. 32, no. 11, pages 3094 - 3105, XP028145193 [A] 8, 18, 23 * ; abstract; page 2, paragraph 2 * DOI: http://dx.doi.org/10.1016/j.biomaterials.2010.12.054 | [A] - KATLAMA, C et al., "Barriers to a Cure: New concepts in targeting and eradicating HIV-1 reservoirs.", Lancet, (20130615), vol. 381, no. 9883, pages 2109 - 2117, XP055223928 [A] 8, 18, 23 * ; page 4, paragraph 3 * DOI: http://dx.doi.org/10.1016/S0140-6736(13)60104-X | [A] - WEISS, L et al., "Human immunodeficiency virus-driven expansion of CD 4+ CD 25+ regulatory T - cells, which suppress HIV-specific CD 4 T- cell responses in HIV-infected patients.", BLOOD, (20041115), vol. 104, no. 10, pages 3249 - 3256, XP055334049 [A] 8, 18, 23 * ; abstract * DOI: http://dx.doi.org/10.1182/blood-2004-01-0365 | Examination | - MICHAEL KOVOCHICH ET AL, "Activation of Latent HIV Using Drug-Loaded Nanoparticles", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, (20110405), vol. 6, no. 4, doi:10.1371/JOURNAL.PONE.0018270, ISSN 1932-6203, pages 1 - 8, XP002720610 DOI: http://dx.doi.org/10.1371/journal.pone.0018270 | by applicant | US8637074 | - MICHAEL KOVOCHICH et al., "Activation of Latent HIV Using Drug-Loaded Nanoparticles", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, (20110405), vol. 6, no. 4, doi:10.1371/journal.pone.0018270, pages 1 - 8, XP002720610 DOI: http://dx.doi.org/10.1371/journal.pone.0018270 |